173 related articles for article (PubMed ID: 17967540)
1. Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist.
Shishido Y; Ito F; Morita H; Ikunaka M
Bioorg Med Chem Lett; 2007 Dec; 17(24):6887-90. PubMed ID: 17967540
[TBL] [Abstract][Full Text] [Related]
2. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton and their pharmacologies.
Watanabe Y; Kitazawa S; Fujii H; Nemoto T; Hirayama S; Nagase H
Bioorg Med Chem Lett; 2012 Apr; 22(8):2689-92. PubMed ID: 22445285
[TBL] [Abstract][Full Text] [Related]
5. Construction of multifunctional modules for drug discovery: synthesis of novel thia/oxa-azaspiro[3.4]octanes.
Li DB; Rogers-Evans M; Carreira EM
Org Lett; 2013 Sep; 15(18):4766-9. PubMed ID: 23991674
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 3,5-disubstituted benzamide analogues of DNK333 as dual NK1/NK2 receptor probes.
Swarna VM; Undem BJ; Korlipara VL
Bioorg Med Chem Lett; 2007 Feb; 17(4):890-4. PubMed ID: 17169559
[TBL] [Abstract][Full Text] [Related]
7. Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of the absolute stereochemical requirements.
Ikeura Y; Ishichi Y; Tanaka T; Fujishima A; Murabayashi M; Kawada M; Ishimaru T; Kamo I; Doi T; Natsugari H
J Med Chem; 1998 Oct; 41(22):4232-9. PubMed ID: 9784098
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.
Crombie AL; Antrilli TM; Campbell BA; Crandall DL; Failli AA; He Y; Kern JC; Moore WJ; Nogle LM; Trybulski EJ
Bioorg Med Chem Lett; 2010 Jun; 20(12):3742-5. PubMed ID: 20471258
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of methyl 2-methyl-7,7-dihalo-5-phenyl-2-azabicyclo[4.1.0]hept-3-ene-4-carboxylates with calcium channel antagonist activity.
Mojarrad JS; Miri R; Knaus EE
Bioorg Med Chem; 2004 Jun; 12(12):3215-20. PubMed ID: 15158789
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands.
Vangveravong S; Xu J; Zeng C; Mach RH
Bioorg Med Chem; 2006 Oct; 14(20):6988-97. PubMed ID: 16837201
[TBL] [Abstract][Full Text] [Related]
11. Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Jiang J; Bunda JL; Doss GA; Chicchi GG; Kurtz MM; Tsao KL; Tong X; Zheng S; Upthagrove A; Samuel K; Tschirret-Guth R; Kumar S; Wheeldon A; Carlson EJ; Hargreaves R; Burns D; Hamill T; Ryan C; Krause SM; Eng W; DeVita RJ; Mills SG
J Med Chem; 2009 May; 52(9):3039-46. PubMed ID: 19354254
[TBL] [Abstract][Full Text] [Related]
12. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor.
Danilova O; Li B; Szardenings AK; Huber BT; Rosenblum JS
Bioorg Med Chem Lett; 2007 Jan; 17(2):507-10. PubMed ID: 17055271
[TBL] [Abstract][Full Text] [Related]
14. Intramolecular formal aza-[3 + 3] cycloaddition approach to indoloquinolizidine alkaloids. A stereoselective total synthesis of (+/-)-tangutorine.
Luo S; Zificsak CA; Hsung RP
Org Lett; 2003 Nov; 5(24):4709-12. PubMed ID: 14627421
[TBL] [Abstract][Full Text] [Related]
15. A solid-phase approach towards the development of 3-aza-6,8-dioxabicyclo[3.2.1]octane scaffolds.
Trabocchi A; Mancini F; Menchi G; Guarna A
Mol Divers; 2003; 6(3-4):245-50. PubMed ID: 15068088
[TBL] [Abstract][Full Text] [Related]
16. Aza-retinoids as novel retinoid X receptor-specific agonists.
Farmer LJ; Marron KS; Canan Koch SS; Hwang CK; Kallel EA; Zhi L; Nadzan AM; Robertson DW; Bennani YL
Bioorg Med Chem Lett; 2006 May; 16(9):2352-6. PubMed ID: 16364638
[TBL] [Abstract][Full Text] [Related]
17. Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of phosphonated carbocyclic 2'-oxa-3'-aza-nucleosides: novel inhibitors of reverse transcriptase.
Chiacchio U; Balestrieri E; Macchi B; Iannazzo D; Piperno A; Rescifina A; Romeo R; Saglimbeni M; Sciortino MT; Valveri V; Mastino A; Romeo G
J Med Chem; 2005 Mar; 48(5):1389-94. PubMed ID: 15743182
[TBL] [Abstract][Full Text] [Related]
19. Efficient synthesis of NK(1) receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation.
Brands KM; Payack JF; Rosen JD; Nelson TD; Candelario A; Huffman MA; Zhao MM; Li J; Craig B; Song ZJ; Tschaen DM; Hansen K; Devine PN; Pye PJ; Rossen K; Dormer PG; Reamer RA; Welch CJ; Mathre DJ; Tsou NN; McNamara JM; Reider PJ
J Am Chem Soc; 2003 Feb; 125(8):2129-35. PubMed ID: 12590540
[TBL] [Abstract][Full Text] [Related]
20. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.
Ye Z; Guo L; Barakat KJ; Pollard PG; Palucki BL; Sebhat IK; Bakshi RK; Tang R; Kalyani RN; Vongs A; Chen AS; Chen HY; Rosenblum CI; MacNeil T; Weinberg DH; Peng Q; Tamvakopoulos C; Miller RR; Stearns RA; Cashen DE; Martin WJ; Metzger JM; Strack AM; MacIntyre DE; Van der Ploeg LH; Patchett AA; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2005 Aug; 15(15):3501-5. PubMed ID: 15982875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
